Entera Bio Ltd. — Director's Dealing 2023

Dec 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2023-12-22

Reporting Person: Toledano Miranda Jayne (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-22	Ordinary Shares, par value NIS 0.0000769 per share	P	23952	$0.71	Acquired	110752	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-22	Warrants (right to buy)	$1.00	P	23952	Acquired	2028-12-22	Ordinary Shares, par value NIS 0.0000769 per share (23952)	Direct

Footnotes

F1: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.